跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
GCGR
首页
药物
GCGR
GCGR
未知生产厂商
订阅
生成 AI 研报
Share to Twitter
Share to Facebook
Share to LinkedIn
Share to Reddit
摘要
临床试验
审批记录
专利
每项发明一条,涵盖美国、欧洲、PCT 与中国的同族专利。
HUMAN ANTIBODIES TO THE GLUCAGON RECEPTOR
EP 3608338 B1
申请人: REGENERON PHARMA
优先权: 2010
EP
US
WO
17 件公开
METHODS OF TREATING SEVERE INSULIN RESISTANCE BY INTERFERING WITH GLUCAGON RECEPTOR SIGNALING
EP 3506940 A1
申请人: REGENERON PHARMA
优先权: 2016
CN
EP
US
WO
10 件公开
Antisense modulation of GCGR expression
US 8865674 B2
申请人: ISIS PHARMACEUTICALS INC
优先权: 2011
CN
US
6 件公开
BISPECIFIC PROTEIN
US 2022153853 A1
申请人: JIANGSU HENGRUI MEDICINE CO
优先权: 2018
CN
EP
US
WO
5 件公开
GLP-1R AND GCGR AGONISTS, FORMULATIONS, AND METHODS OF USE
EP 4106796 A4
申请人: SPITFIRE PHARMA LLC
优先权: 2020
CN
EP
US
WO
5 件公开
Treatment of biliary cirrhosis based on oxyntomodulin analogue GLP-1R/GCGR dual-target agonist peptide
US 11419918 B2
申请人: SHENZHEN TURIER BIOTECH CO LTD
优先权: 2017
CN
US
5 件公开
THERAPEUTIC REGIMENS AND METHODS FOR REDUCING BODY WEIGHT IN A SUBJECT WITH FATTY LIVER DISEASE USING A GLP-1R AND GCGR AGONIST
EP 4587045 A2
申请人: SPITFIRE PHARMA LLC
优先权: 2022
CN
EP
US
WO
4 件公开
siRNA targeting glucagon receptor (GCGR)
US 2008113372 A1
申请人: DHARMACON INC
优先权: 2007
US
4 件公开
Method of reducing the severity of stress hyperglycemia with human antibodies to the glucagon receptor
US 8771696 B2
申请人: REGENERON PHARMA
优先权: 2013
US
4 件公开
GCGR ANTIBODY AND GLP-1 FUSION PROTEIN THEREOF, PHARMACEUTICAL COMPOSITION THEREOF AND APPLICATION THEREOF
EP 3778634 A4
申请人: GMAX BIOPHARM LLC
优先权: 2018
CN
EP
US
3 件公开
第 1 / 8 页
上一页
下一页
药物
反馈